{"disease":{"id":"papillary-renal-cell-cancer","name":"papillary renal cell cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04623502","title":"An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07243067","title":"Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT05411081","title":"Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02761057","title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04071223","title":"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02127710","title":"A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT01130519","title":"A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04981509","title":"Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":65,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01767636","title":"Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03541902","title":"Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":32,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05122546","title":"CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04603365","title":"Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}